Shenzhen Hepalink Releases 2025 Q3 Financial Report
I'm PortAI, I can summarize articles.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited Q3 financial report for 2025, covering the nine months ending September 30. The report, approved by the board, emphasizes transparency and regulatory compliance, which may enhance investor confidence. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$17.59B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments